 SALT LAKE CITY, Nov. 29, 2022 GLOBE NEWSWIRE -- Myriad Genetics, Inc ., NASDAQ: MYGN a leader in genetic testing and precision medicine, today announced multiple presentations of new data at the 2022 San Antonio Breast Cancer Symposium SABCS, including a spotlight discussion on breast cancer risk prediction. 